Montréal company building clinical decision-support software for major depression that uses in-house deep-learning models to predict each patient's probability of remission across first-line treatments.
Canadian innovation builds a brighter tomorrow.
Montréal company building clinical decision-support software for major depression that uses in-house deep-learning models to predict each patient's probability of remission across first-line treatments.
Its privacy policy and terms name Aifred Health Inc. at 1600 rue Notre-Dame Ouest, Montréal; federal corporation 1037787-2 is Active. aifredhealth.com
Health Canada licensed its decision-support software as a Class II device in 2024; Health Canada's device database now lists that licence as cancelled, ending December 9, 2025. health-products.canada.ca
Concluded a North American clinical trial of its AI decision-support tool, run with sites including US Department of Veterans Affairs hospitals, announced January 2024. newswire.ca
Granted US patent 11605463, "Systems and Methods for Treatment Selection", covering AI-guided treatment selection, announced April 2023. newswire.ca
Products Aifred Health publishes on its own site. Each card links to the page it was taken from.
AI clinical decision support
Company describes predicting probabilities of remission against available medications from each patient's characteristics, giving predictions for 10 first-line treatments and combinations, drawing on data from over 9,000 clinical trial participants.
Learn moreGovernment support actually received. Unpublished amounts are left out.
Investissement Québec — Impulsion PME
Aifred announced a Health Canada Class II licence for its software supporting treatment choice in major depression. Health Canada's device database has since listed the licence as cancelled.
Aifred completed its clinical trial, run with partners including the US Department of Veterans Affairs, and began regulatory submissions for its deep-learning decision-support device for major depression.
The US Patent and Trademark Office granted Aifred patent 11605463 covering systems and methods for AI-guided treatment selection.
Sourced from the company's own pages or announcements.
Louisa Petropoulos
Chief Executive Officer
David Benrimoh
Co-founder and Chief Science Officer
Robert Fratila
Co-founder and Vice-President, AI
Terms the company uses about its own work.
Other companies in Digital Health & HealthTech.
Discover companies, track funding, explore career opportunities and stay informed about Canada’s growing tech ecosystem.